Retatrutide

CAS No.: 2381089-83-2

Retatrutide Chemical Structure

Molecular formula:C₂₂₁H₃₄₂N₄₆O₆₈

Molecular weight: 4731.33

Patent period: Compound: 2026 Composition: 2029

Dositive specifications:–

Injection (type II diabetes, OZEMPIC): —

Oral tablets: —

Injection : —

Biological Activity

Retarutide (LY3437943) is a triple agonist peptide of glucagon receptor (GCGR), glucose-dependent insulin-promoting peptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is a peptide composed of about 40 amino acids and contains double targets in its sequence. Retarutide inhibited human GCGR, GIPR and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775nM, respectively. Retarutide can be used for obesity research.

Chemical Properties

ACTIONS	—
CAS NO.	2381089-83-2
FORMULA	C₂₂₁H₃₄₂N₄₆O₆₈
M.WT	4731.33
PURITY	>98%
SYNONYMS	LY3437943
STORAGE	—

Online Inquiry

Obesity

The number of global obesity in 2020 reached 1.211 billion, an increase of 58 million people from 2019, an increase of 5.04% year -on -year.In 2020, the number of obesity in China reached 220 million people, an increase of 1.10 billion from 2019, an increase of 4.77%year -on -year.

Other Drug Peptide

Terzapitide NEW

Tirzepatide causes thyroid C-cell tumors in rats. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined.

Semaglutide NEW

Semaglutide causes thyroid C-cell tumors. It is unknown whether OZEMPIC causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined.

Retatrutide NEW

Retatrutide (LY3437943) is a triple agonist peptide of glucagon receptor (GCGR), glucose-dependent insulin- promoting peptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R), developed for the treatment of obesity and related metabolic disorders.

Cagrilintide NEW

Cagrilintide is an investigational novel long-acting acylated amylin analogue, acting as a nonselective amylin receptor (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake.

Linaclotide NEW

Linaclotide is a potent and selective guanylate cyclase C agonist, developed for the treatment of constipation-type irritable bowel syndrome (IBS-C) and chronic constipation.

BESTBELL